Article: PNP inhibitors selectively kill cancer cells lacking SAMHD1

Purine nucleoside phosphorylase inhibitors (PNP-Is) were developed to ablate transformed lymphocytes. However, only some patients with leukemia benefit from PNP-Is. We provide a molecular explanation: the deoxyribonucleoside triphosphate (dNTP) hydrolase SAM and HD domain-containing protein 1 (SAMHD1) prevents the accumulation of toxic dNTP levels during purine nucleoside phosphorylase inhibition. We propose PNP-Is for targeted therapy of patients with acquired mutations.

Citing Articles

Exploring the potential mechanism of Radix Bupleuri in the treatment of sepsis: a study based on network pharmacology and molecular docking.

Wang H, Xiong W, Laram Y, Hu L, Zhong W, Hu Y BMC Complement Med Ther. 2024; 24(1):347.

PMID: 39354431 PMC: 11446011. DOI: 10.1186/s12906-024-04637-5.

Exploring the potential mechanisms of Rehmannia glutinosa in treating sepsis based on network pharmacology.

Wang H, Laram Y, Hu L, Hu Y, Chen M BMC Infect Dis. 2024; 24(1):893.

PMID: 39217296 PMC: 11366132. DOI: 10.1186/s12879-024-09796-x.

Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors.

Skacel J, Djukic S, Baszczynski O, Kalcic F, Bilek T, Chalupsky K J Med Chem. 2023; 66(10):6652-6681.

PMID: 37134237 PMC: 10226123. DOI: 10.1021/acs.jmedchem.2c02097.

Purine nucleoside phosphorylase deficiency induces p53-mediated intrinsic apoptosis in human induced pluripotent stem cell-derived neurons.

Tsui M, Biro J, Chan J, Min W, Dobbs K, Notarangelo L Sci Rep. 2022; 12(1):9084.

PMID: 35641516 PMC: 9156781. DOI: 10.1038/s41598-022-10935-0.

IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer.

Mandal G, Biswas S, Anadon C, Yu X, Gatenbee C, Prabhakaran S Cancer Res. 2021; 82(5):859-871.

PMID: 34949671 PMC: 8898267. DOI: 10.1158/0008-5472.CAN-21-2376.

References

1.

Schneider C, Oellerich T, Baldauf H, Schwarz S, Thomas D, Flick R . SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2016; 23(2):250-255. DOI: 10.1038/nm.4255. View

2.

Rudd S, Tsesmetzis N, Sanjiv K, Paulin C, Sandhow L, Kutzner J . Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. EMBO Mol Med. 2020; 12(3):e10419. PMC: 7059017. DOI: 10.15252/emmm.201910419. View

3.

Davenne T, Klintman J, Sharma S, Rigby R, Blest H, Cursi C . SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. Cell Rep. 2020; 31(6):107640. PMC: 7225753. DOI: 10.1016/j.celrep.2020.107640. View

4.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs A . SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood. 2013; 123(7):1021-31. PMC: 3924925. DOI: 10.1182/blood-2013-04-490847. View

5.

Knecht K, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L . The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc Natl Acad Sci U S A. 2018; 115(43):E10022-E10031. PMC: 6205433. DOI: 10.1073/pnas.1805593115. View

PNP Inhibitors Selectively Kill Cancer Cells Lacking SAMHD1